An audit of pharmacological therapy on discharge for patients admitted with acute decompensated HFrEF
Pharmacological management of acute decompensated heart failure with reduced ejection fraction (HFrEF) reduces mortality and morbidity[1]. International and local guidelines recommend with class I evidence for the use of renin-angiotensin system inhibitor (RAASi), beta-blocker, miner…